ArticleBritish journal of pharmacology1994
Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro.
Article in British journal of pharmacology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 66 citations in OpenAlex.
- The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects.British journal of clinical pharmacology · 1999Trial
- Article
- Endothelin 2: a key player in ovulation and fertility.Reproduction (Cambridge, England) · 2022Review
- Endothelin.Pharmacological reviews · 2016Review
- Endothelin receptors and their antagonists.Seminars in nephrology · 2015Review
- Endothelin contraction in pig coronary artery: receptor types and Ca(2+)-mobilization.Molecular and cellular biochemistry · 1997Article
- Characterization of endothelin receptors in the human umbilical artery and vein.British journal of pharmacology · 1996Article
- Differential distribution of endothelin peptides and receptors in human adrenal gland.The Histochemical journal · 1996Article
- Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experiments.British journal of pharmacology · 1996Article
- Endothelin receptors in human coronary artery and aorta.British journal of pharmacology · 1996Article
- Endothelin ETA receptor expression in human cerebrovascular smooth muscle cells.British journal of pharmacology · 1995Article
- ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro.British journal of pharmacology · 1995Article
- Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type.British journal of pharmacology · 1995Article
- Characterization of endothelin receptors in rat renal artery in vitro.British journal of pharmacology · 1995Article
- Selectivity of [125I]-PD151242 for human, rat and porcine endothelin ETA receptors in the heart.British journal of pharmacology · 1995Article
- Possible bi-directional link between ET(A) receptors and protein kinase C in rat blood vessels.Mediators of inflammation · 1995Article
- [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature.British journal of pharmacology · 1994Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
1. We have identified the endothelin receptors present in the media of human main stem renal artery and vein and characterized the subtypes mediating vasoconstriction in these blood vessels in vitro. 2. Messenger RNA encoding both ETA and ETB receptors was identified in the smooth muscle layer of human renal artery and vein by reverse transcriptase-polymerase chain reaction assay. In cryostat-cut cross-sections of both vessels autoradiographical visualisation suggested a majority of ETA receptors. Intense binding was obtained to the non-selective ligand [125I]-ET-1 and the ETA-selective [125I]-PD151242 but only weak labelling of sites by the ETB-selective [125I]-BQ3020. 3. ET-1 potently constricted renal artery and vein preparations with EC50 values of 4.06 nM and 1.00 nM, respectively. Sarafotoxin 6b was approximately ten times less potent than ET-1 with EC50 values of 36.3 nM and 13.8 nM respectively. In the renal artery, ET-3 and sarafotoxin 6c showed little or no activity up to 300 nM. Responses to these peptides were more variable in the renal vein. Preparations from three individuals did not respond to ET-3 but in three further cases, although ET-3 was much less potent than ET-1, full dose-response curves were obtained. S6c elicited dose-related contractions in vein preparations from 5/6 individuals and although more potent than ET-1, the maximum response was 30-60% of that obtained to ET-1. 4. ET-1-induced vasoconstriction of renal artery and vein was antagonized by the ETA-selective, BQ123 (3-10 microM). The dose-response curves to ET-1 were displaced in a parallel rightward fashion with no attenuation of the maximum responses. pA2 values were estimated to be 6.8 +/- 0.1 and 6.8 +/- 0.4 for artery and vein respectively.5. These data suggest that mRNA encoding both ETA and ETB receptors is present in the media of human main stem renal artery and vein. However, autoradiographical studies indicate that the majority of ET receptors expressed are of the ETA subtype. The relative potencies of ET-1 and ET-3 as vasoconstrictors of renal blood vessels in vitro is consistent with this being an ETA-mediated response,and therefore whilst responses to S6c indicate that constrictor ETB receptors may be present in renal veins from some individuals these are likely to be of less importance in these blood vessels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.